View Future GrowthEisai 과거 순이익 실적과거 기준 점검 1/6Eisai의 수입은 연평균 -6.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 10.3% 증가했습니다. 매출은 연평균 3.2%의 비율로 증가해 왔습니다. Eisai의 자기자본이익률은 4.8%이고 순이익률은 5.3%입니다.핵심 정보-6.41%순이익 성장률-6.11%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률3.16%자기자본이익률4.84%순이익률5.29%다음 순이익 업데이트15 May 2026최근 과거 실적 업데이트Eisai Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Apr 21Eisai Co., Ltd. to Report Q2, 2026 Results on Nov 05, 2025Mar 06Eisai Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Mar 04+ 2 more updatesEisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025Mar 02+ 3 more updates모든 업데이트 보기Recent updatesEisai Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Apr 21Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in JapanMar 28Eisai Co., Ltd. and Nuvation Bio Inc. Announce Marketing Authorisation Application for Taletrectinib for Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyMar 27Eisai Present New Data on Long-Term Real-World Treatment with LecanemabMar 23Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for NarcolepsyFeb 18Eisai Announces Leqembi® Iqlik™ (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDAJan 28Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®? (Lecanemab)Jan 27Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi (Lecanemab) for Treatment of Early Alzheimer's DiseaseJan 06Eisai Presents the Latest Findings on Time Savings with Continued Treatment with LeqembiDec 04+ 1 more updateEisai Co., Ltd. Presents New Data on Anti-Tau Antibody Etalanetug (E2814) At CTAD 2025Dec 02Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting DoseNov 28+ 1 more updateEisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik™? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track StatusNov 25BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease ConferenceNov 19Eisai Announces Leqembi Approval for IV Maintenance Treatment in the United KingdomNov 14Eisai Co., Ltd. Enters into Settlement Agreement with Torrent Pharmaceuticals LtdNov 09Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular CancerOct 29+ 1 more updateMerck and Eisai Announces Phase 3 LITESPARK-011 Trial Evaluating the Dual Oral Regimen of LENVIMAOct 28Health Canada Grants Authorization for Leqembi (Lecanemab)Oct 27Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)Oct 19Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07+ 1 more updateEisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from StudyOct 03Eisai Announces Leqembi Approval for IV Maintenance Treatment in ChinaOct 01Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24+ 1 more updateEisai Co., Ltd. Announces Etalanetug Granted FDA Fast Track DesignationSep 17Eisai Co., Ltd. Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025Sep 08Eisai Co., Ltd. to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025Sep 04Eisai Co., Ltd. Initiates Rolling Submission of Supplemental Biologics License Application to U.S. Food and Drug Administration for lecanemab-irmb Subcutaneous Autoinjector (SC-AI), LEQEMBI IQLIKSep 03Eisai Announces US FDA Approval of Leqembi IQKLIK®? (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseAug 30Eisai Co., Ltd. and Biogen Inc. Announce That the Anti-Amyloid Beta (Ab) Monoclonal Antibody "LEQEMBI" Has Been Launched in Austria on August 25, 2025 and Will Be Launched in Germany on September 1, 2025Aug 25+ 1 more updateEisai Presents Latest Findings on Lecanemab (Leqembi) At the Alzheimer's Association International ConferenceJul 31Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025Jul 30PRISM BioLab, Co. Ltd. to Present E7386, Co-Developed Through Collaborative Research Between Eisai Co., Ltd., and Lenvatinib MesylateMay 23Eisai Co., Ltd., Annual General Meeting, Jun 18, 2025May 15Eisai Co., Ltd. (TSE:4523) completed the acquisition of EcoNaviSta, Inc. (TSE:5585) from a group of shareholders.May 09MHRA to Evaluate Monthly Intravenous Maintenance Dosing of Leqembi®? for the Treatment of Early Alzheimer's Disease in the UKMay 02Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16Eisai Co., Ltd. to Report Q2, 2026 Results on Nov 05, 2025Mar 06Eisai Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Mar 04+ 2 more updatesEisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28Eisai Announces FDA Approval for Leqembi in USJan 27Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal AdenocarcinomaJan 24Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05Eisai Launches Leqembi in South KoreaNov 28+ 1 more updateEisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15+ 1 more updateEisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the USNov 02Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease ConferenceOct 31Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)Sep 16Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024Sep 04BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great BritainAug 22Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International ConferenceJul 31Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27+ 1 more updateEisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and ResearchJul 23Eisai Announces Approval for the Treatment of Alzheimer's Disease in IsraelJul 12Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in ChinaJun 28Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.May 17Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDAApr 02BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMar 14Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025Mar 02+ 3 more updatesEisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®Feb 23Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in ChinaJan 09Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20Dec 13Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial CarcinomaDec 08Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Nov 09+ 1 more updateEisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's DiseaseOct 27Eisai Co., Ltd., Annual General Meeting, May 22, 2024Oct 20NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.Oct 18Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease ConferenceOct 16Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in JapanSep 25Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung CancerSep 23NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.Sep 08Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell CarcinomaAug 26Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad StudyJul 22+ 1 more updateEisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s DiseaseJul 07Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory CommitteeJun 12Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South KoreaJun 08New minor risk - Dividend sustainability Jun 08Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril AntibodyMay 22Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for LecanemabMay 19매출 및 비용 세부 내역Eisai가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ESAI.Y 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Dec 25808,18642,756419,941159,86030 Sep 25804,39049,369403,660165,39830 Jun 25803,02250,325406,290163,77631 Mar 25789,40046,432396,595171,63331 Dec 24791,66058,792404,859165,95930 Sep 24753,22140,970382,177168,00930 Jun 24733,84532,648387,882169,34731 Mar 24741,75142,406364,084169,02131 Dec 23749,46045,421346,208176,07030 Sep 23759,32948,096346,619174,25730 Jun 23757,07548,874341,916175,64731 Mar 23744,40255,432348,139172,99931 Dec 22737,09826,705373,875169,84830 Sep 22752,50032,233382,752173,32430 Jun 22741,59432,690374,428168,42231 Mar 22756,22647,954356,847171,73831 Dec 21712,93557,311317,150165,41830 Sep 21691,25062,508293,153162,69930 Jun 21679,25359,855282,369161,58431 Mar 21645,94242,119272,568150,29931 Dec 20707,88893,682271,476145,24830 Sep 20713,400120,571261,973139,62830 Jun 20707,203124,523253,516141,21731 Mar 20695,621121,767248,554140,11631 Dec 19661,64696,659244,091146,36730 Sep 19631,97457,725239,503147,86330 Jun 19643,53172,747233,180140,14331 Mar 19642,83463,386223,798144,84431 Dec 18627,36763,714212,469139,10030 Sep 18625,10665,679195,229138,46130 Jun 18611,49954,347186,198140,51431 Mar 18600,05451,845179,915139,57931 Dec 17569,81429,048178,312134,95530 Sep 17554,27630,269178,090123,63930 Jun 17544,02729,425176,249119,50331 Mar 17539,09739,358175,633112,47831 Dec 16530,69655,031175,240110,47130 Sep 16542,31371,812178,825114,42030 Jun 16545,60269,227182,036115,75031 Mar 16547,92254,933188,227122,30731 Dec 15566,43544,886192,375125,39630 Sep 15554,91243,871191,627132,65230 Jun 15554,88543,021192,617135,534양질의 수익: ESAI.Y는 고품질 수익을 보유하고 있습니다.이익 마진 증가: ESAI.Y의 현재 순 이익률 (5.3%)은 지난해 (7.4%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ESAI.Y의 수익은 지난 5년 동안 연평균 6.4% 감소했습니다.성장 가속화: ESAI.Y은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: ESAI.Y은 지난 1년 동안 수익이 감소(-27.3%)하여 Pharmaceuticals 업계 평균(-3.2%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: ESAI.Y의 자본 수익률(4.8%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 01:20종가2026/05/01 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Eisai Co., Ltd.는 21명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research18명의 분석가 더 보기
Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in JapanMar 28
Eisai Co., Ltd. and Nuvation Bio Inc. Announce Marketing Authorisation Application for Taletrectinib for Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyMar 27
Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21
Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for NarcolepsyFeb 18
Eisai Announces Leqembi® Iqlik™ (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDAJan 28
Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®? (Lecanemab)Jan 27
Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26
Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi (Lecanemab) for Treatment of Early Alzheimer's DiseaseJan 06
Eisai Presents the Latest Findings on Time Savings with Continued Treatment with LeqembiDec 04+ 1 more update
Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting DoseNov 28+ 1 more update
Eisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik™? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track StatusNov 25
BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease ConferenceNov 19
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular CancerOct 29+ 1 more update
Merck and Eisai Announces Phase 3 LITESPARK-011 Trial Evaluating the Dual Oral Regimen of LENVIMAOct 28
Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)Oct 19
Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07+ 1 more update
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from StudyOct 03
Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24+ 1 more update
Eisai Co., Ltd. Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025Sep 08
Eisai Co., Ltd. to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025Sep 04
Eisai Co., Ltd. Initiates Rolling Submission of Supplemental Biologics License Application to U.S. Food and Drug Administration for lecanemab-irmb Subcutaneous Autoinjector (SC-AI), LEQEMBI IQLIKSep 03
Eisai Announces US FDA Approval of Leqembi IQKLIK®? (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseAug 30
Eisai Co., Ltd. and Biogen Inc. Announce That the Anti-Amyloid Beta (Ab) Monoclonal Antibody "LEQEMBI" Has Been Launched in Austria on August 25, 2025 and Will Be Launched in Germany on September 1, 2025Aug 25+ 1 more update
Eisai Presents Latest Findings on Lecanemab (Leqembi) At the Alzheimer's Association International ConferenceJul 31
PRISM BioLab, Co. Ltd. to Present E7386, Co-Developed Through Collaborative Research Between Eisai Co., Ltd., and Lenvatinib MesylateMay 23
Eisai Co., Ltd. (TSE:4523) completed the acquisition of EcoNaviSta, Inc. (TSE:5585) from a group of shareholders.May 09
MHRA to Evaluate Monthly Intravenous Maintenance Dosing of Leqembi®? for the Treatment of Early Alzheimer's Disease in the UKMay 02
Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16
Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28
Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal AdenocarcinomaJan 24
Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05
Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15+ 1 more update
Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the USNov 02
Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01
Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease ConferenceOct 31
Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)Sep 16
BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great BritainAug 22
Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International ConferenceJul 31
Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27+ 1 more update
Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and ResearchJul 23
Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.May 17
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDAApr 02
BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMar 14
Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial CarcinomaDec 08
Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Nov 09+ 1 more update
Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's DiseaseOct 27
NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.Oct 18
Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease ConferenceOct 16
Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in JapanSep 25
Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung CancerSep 23
NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.Sep 08
Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell CarcinomaAug 26
Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad StudyJul 22+ 1 more update
Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s DiseaseJul 07
Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory CommitteeJun 12
Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South KoreaJun 08
Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril AntibodyMay 22
Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for LecanemabMay 19